Group 1 - The stock price of Haobor is reported at 112.90 yuan, down 1.85 yuan or 1.61% from the previous trading day, with a trading volume of 10,347 hands and a transaction amount of 118 million yuan [1] - Haobor's main business involves the research, production, and sales of in vitro diagnostic reagents, primarily used in the diagnosis of allergies and autoimmune diseases. The company holds 62 patents and 230 product registration certificates, utilizing core technologies such as enzyme-linked immunosorbent assay and nano-magnetic chemiluminescence technology [1] - According to the 2025 semi-annual report, Haobor achieved a revenue of 190 million yuan in the first half of the year, a year-on-year decrease of 6.48%, with a net profit attributable to shareholders of 12.17 million yuan, down 39.10% year-on-year. The decline in performance is mainly attributed to a decrease in product sales scale and an increase in costs [1] - In the second quarter, the revenue was 112 million yuan, a year-on-year decrease of 4.4%, and the net profit was 10.53 million yuan, down 34.9% year-on-year [1] Group 2 - In terms of capital flow, Haobor experienced a net outflow of 11.20 million yuan from main funds on the day, with a cumulative net outflow of 3.78 million yuan over the past five days [2]

Core Insights - The core viewpoint of the news is the performance and holdings of the Agricultural Bank of China Healthcare Stock Fund, which has shown significant growth in recent months and has a diversified portfolio in the healthcare sector [1]. Fund Performance - The latest net value of the Agricultural Bank of China Healthcare Stock Fund is 1.9772 yuan, reflecting a growth of 1.81% [1]. - The fund's return over the past month is 9.64%, ranking 129 out of 328 in its category [1]. - Over the last six months, the fund has achieved a return of 47.35%, ranking 12 out of 316 [1]. - Year-to-date, the fund has a return of 45.00%, ranking 18 out of 316 [1]. Fund Holdings - The top ten holdings of the Agricultural Bank of China Healthcare Stock Fund account for a total of 51.10% of the portfolio, with the following key positions: - Heng Rui Medicine: 8.16% - Zai Lab: 7.99% - Xin Li Tai: 5.84% - Rejig Bio: 5.63% - Kelun Pharmaceutical: 5.02% - HAO OBO: 4.36% - BeiGene: 3.61% - Yifang Bio: 3.58% - Aosaikang: 3.52% - Bid Pharma: 3.39% [1]. Fund Background - The Agricultural Bank of China Healthcare Stock Fund was established on February 10, 2015, and as of June 30, 2025, it has a total scale of 1.441 billion yuan [1]. - The fund manager is Meng Yuan, who has a master's degree and has held various positions in the fund management industry, including roles at Bank of China Fund Management and Agricultural Bank of China Asset Management [1].

Group 1 - The company held its 19th meeting of the third supervisory board on August 13, 2025, with all three supervisors present, and the meeting was deemed legal and effective [3] - The supervisory board approved the company's 2025 semi-annual report and its summary, confirming that the report's preparation and review processes complied with relevant laws and regulations [4] - The supervisory board also approved the special report on the storage and actual use of raised funds for the first half of 2025, stating that the management of raised funds adhered to regulatory requirements [6] Group 2 - The company plans to change its auditing firm to Ernst & Young Huaming, as the previous firm, Lixin, has provided services for ten consecutive years [24][32] - The decision to change the auditing firm was based on the need for new auditing services aligned with the company's business development and future audit requirements [32] - The company has communicated with both the outgoing and incoming auditing firms regarding this change, and both parties have no objections [32] Group 3 - The company reported that as of June 30, 2025, it had raised a total of RMB 555.86 million from its initial public offering, with a net amount of RMB 496.47 million after deducting related expenses [12][13] - By June 30, 2025, the company had used RMB 515.85 million of the raised funds for projects and incurred RMB 59.39 million in issuance costs, with a remaining balance of RMB 3.06 million in the raised funds account [13] - The company has implemented strict management of raised funds, ensuring they are stored in dedicated accounts and used for their intended purposes [14] Group 4 - The company has proposed changes to its registered capital and amendments to its articles of association, which were approved during the board meeting on August 13, 2025 [38][39] - The registered capital increased from RMB 630.58 million to RMB 634.80 million following the completion of the stock incentive plan [38] - The amendments to the articles of association will be finalized based on the approval from the relevant registration authority [39] Group 5 - The company announced the convening of its second extraordinary general meeting of 2025, scheduled for September 1, 2025, to discuss various proposals [41][42] - The meeting will utilize a combination of on-site and online voting methods, allowing shareholders to participate remotely [43] - Shareholders must register for the meeting by August 29, 2025, and can delegate representatives to attend [55]

Meeting Details - The 19th meeting of the third Supervisory Board of Jiangsu Haoaobo Biopharmaceutical Co., Ltd. was held on August 13, 2025, with all three supervisors present [1] - The meeting was convened in accordance with the Company Law of the People's Republic of China and the company's articles of association, ensuring the legality and validity of the resolutions [1] Financial Report Review - The Supervisory Board reviewed the company's 2025 semi-annual report, confirming that its preparation and review procedures comply with relevant laws and internal management regulations [1] - The report accurately reflects the company's financial status and operating results for the first half of 2025, with all members of the Supervisory Board ensuring the information disclosed is true, accurate, and complete [1] Fund Management - The Supervisory Board assessed the management of raised funds, confirming compliance with the regulations governing the management of raised funds and the company's fundraising management system [2] - The company has stored and utilized the raised funds in a dedicated account, with no violations or damages to the interests of the company and its shareholders [2] Auditor Appointment - The Supervisory Board approved the appointment of Ernst & Young Hua Ming LLP as the auditing firm for the company's 2025 financial report and internal control audit, citing their qualifications and experience [3] - The resolution received unanimous approval from all supervisors, with 100% of the voting rights in favor [3]

证券代码：688656 证券简称：浩欧博 公告编号：2025-047 江苏浩欧博生物医药股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 召开地点：公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等有关规定执行。 （七） 涉及公开征集股东投票权 不适用 二、 会议审议 ...

情况 州片区苏州工业园区东堰里路9号 江苏浩欧博生物医药股份有限公司2025 年半年度报告 公司代码：688656 公司简称：浩欧博 江苏浩欧博生物医药股份有限公司 江苏浩欧博生物医药股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险，敬请查阅本 报告第三节"管理层讨论与分析"中"四、风险因素"的相关内容。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人JOHN LI、主管会计工作负责人张扬清及会计机构负责人（会计主管人员）韩书 艳声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 不适用 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、发展战略等前瞻性陈述，不构成公司对投资者的 实质承诺， ...

规划，投资者应当到 www.sse.com.cn 网站仔细阅读半年度报告全文。 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险，敬请查阅本报告第三节 "管理层讨论与分析"中"四、风险因素"的相关内容。 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 江苏浩欧博生物医药股份有限公司2025 年半年度报告摘要 公司代码：688656 公司简称：浩欧博 江苏浩欧博生物医药股份有限公司 江苏浩欧博生物医药股份有限公司2025 年半年度报告摘要 第一节 重要提示 公司股票简况 | 股票种类 | 股票上市交易所 | 股票简称 | | 股票代码 变更前股票简称 | | | --- | --- | --- | --- | --- | --- | | A股 | 上海证券交易所科创板 | 浩欧博 | 688656 | 不适用 | | | 公司存托凭证简况 | | | | | | | □适用 √不适用 | | | | | | | 联系人和联系方式 | | | | | | | 联系人和联系方式 | | 董事会秘书（信息披露境内代表） | | | | | 姓名 | | 谢爱香 | | | | | ...

（文章来源：证券日报） 证券日报网讯 8月14日晚间，浩欧博发布公告称，公司第三届监事会第十九次会议审议通过了《关于变 更公司2025年度审计机构的议案》等多项议案。 ...

证券日报网讯8月14日晚间，浩欧博发布公告称，公司于2025年8月13日召开第三届董事会第二十五次会 议，审议通过了《关于提名公司第三届董事会独立董事的议案》，同意提名钱世政先生、彭建刚先生为 公司第三届董事会独立董事候选人，任期自公司股东大会审议通过之日起至第三届董事会任期届满之日 止。 ...

Group 1 - The core point of the article is that Haobo (688656) reported a decline in both revenue and net profit for the first half of 2025 [1] Group 2 - In the first half of the year, the company achieved revenue of approximately 190 million yuan, representing a year-on-year decrease of 6.48% [1] - The net profit attributable to the company was 12.1692 million yuan, which reflects a year-on-year decrease of 39.1% [1]